Abstract: The present disclosure provides biological markers which are molecular and cellular antecedents of rheumatoid arthritis (RA) flares. The present disclosure provides RNA and protein markers that can predict an RA flare one or two weeks prior to the flare. The present disclosure further provides blood circulating cells, particularly pre-inflammatory mesenchymal cells, which are cellular precursors and indicators of an impending RA flare. The present disclosure further provides methods, kits and markers for identification and monitoring of flares in RA patients and their application as markers and targets in and for treatment of rheumatoid arthritis and conditions induced or related to rheumatoid arthritis.

Abstract: The present invention provides methods for rapid and efficient isolation and characterization of nucleic acid, particularly RNA, from small volume and self-collected samples, particularly saliva samples, to determine the presence or absence of infectious agent RNA, particularly viral RNA, particularly infectious viral RNA, particularly coronavirus. The invention provides methods for isolation and evaluation of infectious agent RNA from saliva samples, particularly viral agents, particularly coronavirus. The invention further provides methods and strategies for pooling samples and RNA to determine the presence or absence of infectious agent RNA, particularly viral RNA, particularly infectious viral RNA, particularly coronavirus, with regard to large numbers of samples at one time and in a single pooled test format.

Abstract: The present invention provides biological markers which are molecular and cellular antecedents of rheumatoid arthritis (RA) flares. The invention provides RNA and protein markers that can predict an RA flare one or two weeks prior to the flare. The invention further provides blood circulating cells, particularly pre-inflammatory mesenchymal cells, which are cellular precursors and indicators of an impending RA flare. The present invention further provides methods, kits and markers for identification and monitoring of flares in RA patients and their application as markers and targets in and for treatment of rheumatoid arthritis and conditions induced or related to rheumatoid arthritis.

Abstract: The present invention provides methods for isolation and characterization of nucleic acid, particularly RNA, from small volume and self-collected samples, including fingerstick blood samples, swabs and saliva samples. The RNA derived is intact and of sufficient quality and quantity for RNA analysis, longitudinal RNA sequencing and global transcriptomic profiling.

Abstract: Processes to identify variants that affect biochemical regulation are described. Generally, models are used to identify variants that affect biochemical regulation, which can be used in several downstream applications. A pathogenicity of identified variants is also determined in some instances, which can also be used in several. Various methods further develop research tools, perform diagnostics, and treat individuals based on identified variants.

Abstract: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.

Abstract: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.

Abstract: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.

Abstract: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.

Abstract: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.

Abstract: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.

Abstract: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.

Abstract: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity.

Abstract: Compositions and methods for identifying and/or modulating RNA transcripts and/or genes involved in fragile X syndrome and other associated disorders are provided. In particular, RNA targets for fragile X mental retardation protein (FMRP) have been identified by a novel monoclonal antibody to FMRP and a consensus sequence for the RNA binding region has been identified. Arrays for identifying compounds, proteins, nucleotides, and the like that modulate the RNA targets or associated genes are provided. Additionally, methods for modulating RNA targets are provided.

Abstract: Recognition of the role of a cellular immune response to immune-privileged antigens in the etiology of paraneoplastic syndromes and tumor immunity has provided diagnostic and therapeutic methods for the detection of paraneoplastic antigen-specific cells, enhancing tumor immunity by increasing the population of cytotoxic T lymphocytes (CTLs), and suppressing cellular immunity to treat the paraneoplastic syndrome. Methods for the detection of memory and cytotoxic T lymphocytes are provided which utilize immune-privileged antigens or their peptides. Enhanced CTL production is provided by stimulating antigen presenting cells in vitro with immune-privileged antigen, with and without further exposure to T lymphocytes, prior to reintroduction of either the antigen-presenting cells and/or the T lymphocytes into the patient.

Abstract: Agents and method are described for inducing apoptosis in normal and diseased cells by antagonizing the interaction between onconeural antigens and apoptosis-inducing proteins, such as transcription factors. The antagonism of the interaction leads to increased bioavailability of the protein, which then directly or indirectly induces cell cycle genes. In dysproliferative cells, such gene activation and induction of cell cycle genes leads to apoptosis and death of dysproliferative cells. Therapies are directed to the treatment of diseases such as cancer. Normal cells, such as germ cells, may be treated by the agents to undergo apoptosis, for example, in the induction of sterility. Methods for the identification of suitable agents of the present invention are described by determining the extent of interference of binding between onconeural antigens and their fragments and apoptosis-inducing proteins and their fragments, in cell-free and cell-based assays.

Abstract: Methods are provided for preventing a cellular immune response to a pre-selected antigen by ex vivo or in vivo methods whereby dendritic cell maturation is permitted to occur in the absence of effective CD4+ T cell help. Under these conditions, elimination of cytotoxic T cells is achieved. The methods may be used for the prophylaxis of an undesired immune response to an autoimmune disease antigen, a transplant antigen, or reducing an exaggerated immune response to a antigen.

Abstract: An isolated nucleic acid sequence encoding Ri paraneoplastic antigenic polypeptide is provided by this invention. This invention also provides a purified Ri antigenic polypeptide and compositions containing the purified Ri antigenic polypeptide. Further provided by this invention is a antibody directed to an epitope on the Ri paraneoplastic antigenic polypeptide. Compositions containing this antibody also are provided by this invention. This invention also provides methods of diagnosis and treatment using the compositions described hereinabove.